Therapeutic area intelligence for Androgen Receptor Inhibitor with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 1

Companies

Sandoz →

Assets

Astellas →

Enzalutamide →

Janssen →

Recent signals(4)

RegulatoryJuly 30, 2026

FDA Accepts Supplemental Application for XTANDI (Enzalutamide)

The FDA has accepted a supplemental application for XTANDI (enzalutamide) from Astellas.

StrategyJuly 28, 2026

Sandoz's Enzalutamide ANDA216068 Receives Approval Status from FDA

Sandoz's application for Enzalutamide (ANDA216068) has received an approval status (AP) from the FDA.

RegulatoryJuly 8, 2026

FDA Accepts Supplement Application for ERLEADA (Apalutamide)

The FDA has accepted a supplemental application for ERLEADA, a drug developed by Janssen Biotech.

StrategyJuly 5, 2026

Sandoz Receives FDA Approval for Enzalutamide ANDA216068

Sandoz has received FDA approval for its Abbreviated New Drug Application (ANDA) for Enzalutamide.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.